2(22) 2010
https://doi.org/10.33573/ujoh2010.02.071
Basanets A. V., Andruschenko T. A.
CARDIOVASCULAR DISEASES UNDER THE ACTION OF OCCUPATIONAL FACTORS
SI «Institute for occupational health of AMS of Ukraine», Kyiv
Full article (PDF), UKR
The problem of cardiovascular diseases of different contingents of the working population is discussed in the article. Occupational factors of the modern production, which can occur as etiological agents of CVD, pathogenesis, peculiarities of clinical picture and the course of cardiovascular diseases under the influence of the working environment have been defined. Actual problems, concerning developing preventive measures for cardiovascular disease and their complications, which can result in disability and reduction of life duration of the working population have been elucidated.
Key words: cardiovascular diseases, professional factors, pathogenesis, clinical picture, prevention
References
- Kundiev Yu. I., Nahorna A.M. (2007), Profesiynezdorov'ya v Ukrayini, epidemiolohichnyyanaliz [Occupational health in Ukraine. Epidemiologicalanalysis], Avicenna, Kiev, Ukraine.
- Kannel W. B. Epidemiology and prevention of cardiac failure: Framingham Study insights / W. B. Kannel / / Europ. Heart J.- 1987.- V. 8, Suppl. F.- P. 23-26. https://doi.org/10.1093/eurheartj/8.suppl_F.23
- Baranov V. S. Genypredraspolozhennostiigeneticheskiypasport / V. S. Baranov, M. V. Aseyev, V. Ye. Baranova // Priroda.- 1999.- No 3.- S. 13-17.
- Raptovasmert, reanimatsiyaiintensyvnaterapiya / Volnyy I. F., Pasternak.H. I., Pyeshkov YU. V., Tkacheva M. YU. // Ekstrenamedychnadopomohana do hospitalʹnomuetapi.-Luhansk.- 2006.- S. 29-34.
- Voronkov L. H. Khronichnasertsevanedostatnist: Praktychnyyposibnyk / L. H. Voronkov.- K.: Chetvertakhvylya, 2004.- 198 s.
- Mazur N. A. Rekomendatsiyiporaptoviysmerti / RosiyskyyKonhreskardiolohiv. Dopovid (prezentatsiyanatsionalnykhrekomendatsiy VNOK) / N. A. Mazur.- Moskva, 2003.- S. 190.
- Kompleksnaprofilaktykaraptovoyismerti, infarktumiokarda, mozkovohoinsultu ta yikhnaslidkiv u hirnykivvuhilnykhshakht, metodychnirekomendatsiyi / [Valutsyna V. M., Cherkesov V. V., Perederiy H. S. ta in.].- Kyiv, 2008.- S. 31.
- Okorokov A. N. Raptovasertsevasmert (pervynnazupynkasertsya) / A. N. Okorokov // Diahnostykakhvorobvnutrishnikhorhaniv. Diahnostykakhvorobsertsyaisudyn.- Moskva: Medychnaliteratura.- 2002.- T. 6.- S. 414-423.
- Kryvohlaz B. A. Zakhvoryuvannyasertsevo-sudynnoyisystemy, yikhprofilaktykailikuvannya (v dopomohulektoram) / B. A. Kryvohlaz.-Kyiv, 1957.- S. 22.
- Hirnychyy Zakon Ukrayiny (st. 40) // Postanova Kabinetu Ministriv vid 18 lyutoho 2004 r. No 186 "ProvnesennyazminpoProhramipidvyshchennyabezpekypratsinavuhilnykhshakhtakh" (p. 99).
- Korzh YE. V. Patolohiyalehenisertsya u shakhtariv: Monohrafiya / Ye. V. Korzh, V. V., Mukhin.-Donetsk: Kashtan, 2004.- S. 164.
- Kobets H P. Ishemichnakhvorobasertsya u hirnychykhpratsivnykiv / H. P. Kobets, V. V. Cherkesov, R. A. Kopytina.-Kyiv: Zdorov'ya.- 1995.- S. 161.
- Trakhtenberg I.M., Babayan A.S., Kandaryan K.A. (1992), Khimichnifaktoryvyrobnychohoseredovyshchaisertsevo-sudynnasystema [Chemical factors of the work environment and cardio-vascular system], Aiastan, Yerevan, Armenia.
- Otsinka ta modyfikatsiyaryzykusertsevo-sudynnykhuskladnen u khvorykh z arterialnoyuhipertenziyeyu (metodychnirekomendatsiyi) / [Zharinov O. Y., Bobrova O. V., Vyeryezhnikova H. P. ta in.].- Kyiv.- 2009.- S. 18.
- Dzyak G. V. Sutochnoyemonitorirovaniyearterial'nogodavleniya / G V. Dzyak, T. V. Kolesnik, YU. N. Pogoretskiy.- Dnepropetrovsk, 2005.- S. 200.
- RekomendatsiyiUkrayinskohotovarystvakardiolohiv z profilaktykytalikuvannyaarterialnoyihipertenziyi.- K., 2008.- S. 76.
- The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension and of the European society of Cardiology. 2007 Guidelines for the management of arterial hypertension // Europ. Heart J.- 2007.- V.28.- P. 1462-1536.
- Chobanian A.V., Bakris G.L., Black H.R., et al., and the National High Blood Pressure Education Program Coordinating Committee, The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. The JNC 7 report // JAMA.- 2003.- V. 289.- P. 3560 -3572. https://doi.org/10.1001/jama.289.19.2560
- Boytsov S. A. Desyat' let poiskageneticheskoyosnovygipertonicheskoybolezni: trudnostiiperspektivy / S. A. Boytsov // Genetika.- 2002.- T. 8, No 5.- S. 56-64
- Kliniko-geneticheskiyeaspektygipotenzivnogootveta i obratnogorazvitiyagipertrofiilevogozheludochka u bol'nykharterial'noygipertoniyey / [Moiseyev V. S., KotovskayaYu. V., Kobalava ZH. D. i dr.] // Terapevticheskiyarkhiv.- 2002.- No 10.- C. 30-37.
- Geneticheskiyemarkerygipertrofiimiokardalevogozheludochka / [Karpov R. S., Puzyrev K. V., Stepanov V. A. i dr.] // Arterial'nayagipertenziya.-1999.- T 5.- S. 54.
- Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow mediated vasodilatation in patients with coronary disease (BANF Study) / [Anderson T. J., Elstein E., Haber H. et al.].- J Am CollCardiol. 2000.- No 35.- P 60-66. https://doi.org/10.1016/S0735-1097(99)00537-9
- Konchalovskaya N. M. Serdechno-sosudistayasistemaprideystviiprofessional'nykhfaktorov / N. M. Konchalovskaya.-M.: Meditsina, 1976-S. 256.
- K otsenkeroliproizvodstvennykhfaktorovglubokikhugol'nykhshakht v razvitiiishemicheskoybolezniserdtsa u gornorabochikh / [Kobets' G P., Cherkesov V. V., Kopytina R. A. i dr.] // Gigiyenatruda i profpatologiya.- M, 1992.- S. 7-9.
- Kholopkina N.A., Gorblyanskiy YU. YU. Monitoring faktorovriskavozniknoveniyaserdechno-sosudistykhzabolevaniy u shakhtorov, stradayushchikharterial'noygipertoniyey / N. A. Kholopkina, YU. YU. Gorblyanskiy // Gigiyenatruda i profpatologiya.- M., 2003.- S. 59-61.
- Drobyshev V. V., Yefremov A. V., Loseva M. I. i dr. // Terapevticheskiyarkhiv.-2002.- No 10.- S. 62-65. https://doi.org/10.1055/s-2002-19513
- Profilaktika, diagnostika i lecheniyepervichnoyarterial'noygipertenzii v RossiyskoyFederatsii: PervyydokladNauchnogoobshchestvapoizucheniyuarterial'noygipertoniiVserossiyskogonauchnogoobshchestvakardiologov i Mezhvedomstvennogosonetaposerdechno-sosudistymzabolevaniyam (DAG Í) // Kardiologiya.- 2000.- No 11.- S. 65-93.
- Organov R. G // Vrach.- 2001.- No 7.- S. 3-6.
- Kobalava ZH. D., Kotovskaya YU. V. // Arterial'nayagipertoniya v voprosakhiotvetakh.-M., 2002.- S. 35-37.
- Epidemiologiyasvyazannykh s rabotoybolezney i neschastnykhsluchav // Dokladob"yedinennogokomiteta MOT VOZ poprof. gigiyene. Seriyatekhn. doklad., 10-y.- Zheneva, 1991.
- RekomendatsiyiYevropeyskohotovarystva z hipertenziyitaYevropeyskohokardiolohichnohotovarystva z likuvannyaarterialnoyihipertenziyi // JournalofHyper- tention.- 2003.- V. 21.- P. 1011-1053.
- Novyyerekomendatsiipodiagnostikeilecheniyuarterial'noygipertenziidlyaYevropyiSevernoyAmeriki (kommentariy) / Yu. N. Sirenko (2007) // Medicine Review.-2008.- No 2 (02).- C. 8-11.
- Birkenhager-Essential hypertension / Jan A. Staessen, Jiguang Wang, Giuseppe Bianchi, Willem H // LANCET, 2003.-V. 361.- P 1629-41. https://doi.org/10.1016/S0140-6736(03)13302-8
- Novyyepredstavleniya o patogenezekhronicheskoyserouglerodnoyintoksikatsii / KundievYu. I., Popov T.A., KrasnyukYe.P., Lukhtay V.A. // Vrachebnoyedelo.- 1978.- S. 7, 9-11.
- Vorob'yev Ye. I. Radiatsionnayakardiologiya / Ye. I. Vorob'yev.-M.: Atomizdat, 1971.
- Uroven' endoteliyzavisimoyvazodilatatsii i aktivnost' angiotenzinprevrashchayushchegofermentakakkriteriyterapiibol'nykh s myagkoy i umerennoyarterial'noygipertoniyey / [Yakimenko O. N., Gomazkov O. A., Ektova T. V. i dr.] // Kardiologiya.- 2005.- No 2.- S. 15-19.
- Moiseyev V. S. Arterial'nayagipertoniya u litsstarshikhvozrastnykhgrupp / V. S. Moiseyev, ZH. D. Kobalava.-Moskva: Meditsinskoyeinformatsionnoyeagentstvo, 2002.- S. 80-95.
- Vorob'yevYe. I. Sostoyaniyekletokmiokardakrolikovposlelokal'nogooblucheniyaoblastiserdtsa / Vorob'yevYe. I., Stepanov R P. // Radiobiologiya.- 1973.- No 6.- S. 844-849.
- Evans W. E. Pharmacogenomics-Drug Disposition, Drug Targets, and Side Effects / Evans W. E., McLeod H. L. // N.Engl.J. Med.- 2003.- V. 348, No 6.- P 538-546. https://doi.org/10.1056/NEJMra020526
- Maternal cigarette smoking, metabolic gene polymorphism, and infant birth weight / [Wang X., Zuckerman B., Pearson C. at al.] // J.A.M.A.- 2002.- V. 287.- P 195-202. https://doi.org/10.1001/jama.287.2.195
- Karnaukh N. G. Zabolevayemost' ifunktsional'noyesostoyaniyeserdechno-sosudistoysistemy u metallurgov / Karnauk N. G, Pavlenko M. Ye. // Sb. Gigiyenatruda.- 1978.- Vyp. 14.- S. 28-31.
- Gorban' L. N. Vliyaniyeusloviytrudanasostoyaniyezdorov'ya i zabolevayemost' rabotayushchikh v svarochnomproizvodstve / Gorban' L. N., KrasnyukYe. P., Faktorov I. Ye. // Sb. Gigiyenatruda.- 1963.- Vyp. 19.- S. 40-49.
- Relationship between circadian blood pressure patterns and progression of early carotid atherosclerosis. A 3-year follow-up study / [Sander D., Kukla C., Klingelhofer J. et al.] // Circulation.-2000.- V. 102.- P 1536-1541. https://doi.org/10.1161/01.CIR.102.13.1536
- Respiratory disease and cardiovascular morbidity / Koskela R.- S., Mutanen P., Sorsa J.- A., Klockars M. // Occupational and Environmental Medicine.- 2005.- V. 62.- P 650-655. https://doi.org/10.1136/oem.2004.017111
- Villeneuve P. J. Coronary heart disease mortality among Newfoundland fluorspar miners. Department of Preventive Medicine and Biostatistics, University of Toronto, Laboratory Centre for Disease Control, Health Canada / Villeneuve P J., Morrison H. I. // Scandinavian journal of work, environment & health ISSN 0355-3140.1997.- V. 23.- No 3.- P 221-226 (29 ref.). https://doi.org/10.5271/sjweh.202
- Vascular-Protective Effects of High-Density Lipoprotein Include the Downregulation of the Angiotensin II Type 1 Receptor/ [Sophie Van Linthout, Frank Spillmann, Mario Lorenz et al.] // Hypertension.- 2009.- V. 53.- P. 587-589. https://doi.org/10.1161/HYPERTENSIONAHA.108.118919
- Cardiac Overexpression of Angiotensin Converting Enzyme 2 Protects the Heart From Ischemia-Induced Pathophysiology / [Shant Der Sarkissian, Justin L. Grobe, Lihui Yuan et al.] // Hypertension.- 2008.- V. 51.- P 712. https://doi.org/10.1161/HYPERTENSIONAHA.107.100693
- Mohan K. Raizada. Potential of Gene Therapy Strategy for the Treatment of Hypertension / Mohan K. Raizada, Shant Der Sarkissian // Hypertension.-2006.- V. 47.- P. 6. https://doi.org/10.1161/01.HYP.0000196685.91424.01
- Der Sarkissian S., Huentelman M.J., Stewart J., Katovich M.J., Raizada M.K. ACE2: A novel therapeutic target for cardiovascular diseases. ProgBiophysMolBiol. 2005:Jul 8.
- Pachori A.S., Huentelman M.J., Francis S.C., Gelband C.H., Katovich M.J., Raizada M.K. The future of hypertension therapy: sense, antisense, or nonsense? Hypertension.- 2001.- V. 37.- P. 357-364. https://doi.org/10.1161/01.HYP.37.2.357
- Blakita I. V. Biokhimicheskiyeizmeneniya v miokardeprikhronicheskomvozdeystviietilmerkurkhlorida i khlorofosa / I. V. Blakita // Gig. tr. i prof. zd-ya.- 1986.- No 5.- S. 46-47.
- Gene therapy with human tissue kallikrein reduces hypertension and hyperinsulinemia in fructose-induced hypertensive rats / [Zhao C., Wang P., Xiao X. et al.] // Hypertension.- 2003.- V. 42.- P. 1026-1033. https://doi.org/10.1161/01.HYP.0000097603.55404.35
- Transient decrease in high blood pressure by in vivo transfer of antisense oligodeoxynucleotides against rat angiotensinogen / [Tomita N., Morishita R., Higaki J. et al.] // Hypertension.- 1995.- V. 26.- P. 131-136. https://doi.org/10.1161/01.HYP.26.1.131
- Galli S. M. Angiotensin II AT(1A) receptor antisense lowers blood pressure in acute 2-kidney, 1-clip hypertension / Galli S. M., Phillips M. I. // Hypertension.- V. 38,-P. 674-678. https://doi.org/10.1161/hy09t1.095207
- Chronic control of high blood pressure in the spontaneously hypertensive rat by delivery of angiotensin type 1 receptor antisense / Lyer S. N., Lu D., Katovich M. J., Raizada M.K // Proc Natl AcadSci U S A.- 1996.- V. 93.- P. 9960 -9965. https://doi.org/10.1073/pnas.93.18.9960
- Blood pressure-independent attenuation of cardiac hypertrophy by AT(1)R-AS gene therapy / [Pachori A. S., Numan M. T., Ferrario C.M. et al.] // Hypertension.- V. 39.- P. 969-975. https://doi.org/10.1161/01.HYP.0000017827.63253.16
- The future of hypertension therapy: sense, antisense, or nonsense? / [Pachori A. S., Huentelman M. J., Francis S.C. et al.] // Hypertension.-2001.- V. 37.- P. 357-364. https://doi.org/10.1161/01.HYP.37.2.357
- Sustained inhibition of angiotensin I-converting enzyme (ACE) expression and long-term antihypertensive action by virally mediated delivery of ACE antisense cDNA / [Wang H., Katovich M. J., Gelband C. H. et al.] // Circ Res.- 1999.- V. 85.- P. 614-622. https://doi.org/10.1161/01.RES.85.7.614
- Akhmeteli M. A. Epidemiologicheskiyeissledovaniyaserdechno-sosudistykhzabolevaniy i ikhprofilaktika / Akhmeteli M. A. // Sov. zdravookh.- 1982.- No 5.- S. 20-23.
- Attenuation of hypertension and heart hypertrophy by adeno-associated virus delivering angiotensinogen antisense / Kimura B., Mohuczy D., Tang X., Phillips M. I. // Hypertension.- 2001.- V. 37.- P. 376-380. https://doi.org/10.1161/01.HYP.37.2.376
- Antisense inhibition of beta(1)-adrenergic receptor mRNA in a single dose produces a profound and prolonged reduction in high blood pressure in spontaneously hypertensive rats /Zhang Y. C., Bui J. D., Shen L., Phillips M. I // Circulation.-2000.- V. 101.- P. 682-688. https://doi.org/10.1161/01.CIR.101.6.682
- Angiotensin II-induced cardiac hypertrophy and hypertension are attenuated by epidermal growth factor receptor antisense / [Kagiyama S., Eguchi S., Frank G.D. et al.] // Circulation.- 2002.- V. 106.- P 909-912. https://doi.org/10.1161/01.CIR.0000030181.63741.56
- Antisense to epidermal growth factor receptor prevents the development of left ventricular hypertrophy / Kagiyama S., Qian K., Kagiyama T., Phillips M. I. // Hypertension.- 2003.- V. 41.- P 824-829. https://doi.org/10.1161/01.HYP.0000047104.42047.9B
- Adrenomedullin gene delivery attenuates hypertension, cardiac remodeling, and renal injury in deoxycorticosterone acetate-salt hypertensive rats / Dobrzynski E., Wang C., Chao J., Chao L. // Hypertension.- 2000.- V. 36.- P 995-1001. https://doi.org/10.1161/01.HYP.36.6.995
- Lin K. F. Human atrial natriuretic peptide gene delivery reduces blood pressure in hypertensive rats / Lin K. F., Chao J., Chao L. // Hypertension.- 1995.- V. 26.- P 847-853. https://doi.org/10.1161/01.HYP.26.6.847
- Wang C. Direct gene delivery of human tissue kallikrein reduces blood pressure in spontaneously hypertensive rats / Wang C., Chao L., Chao J. // J Clin Invest.- 1995.- V. 95.- P 1710-1716. https://doi.org/10.1172/JCI117847
- Human tissue kallikrein attenuates hypertension and secretes into circulation and urine after intramuscular gene delivery in hypertensive rats / [Zhang J. J., Wang C., Lin K. F. et al.] // ClinExpHypertens.- 1999.- V. 21.- P 1145-1160. https://doi.org/10.3109/10641969909052194
- Babayan E. A. Gigiyenicheskayareglamentatsiyakhimicheskikhveshchestv v okruzhayushcheysrede s uchetomikhdeystviyana SSS / E. A. Babayan // V kn.: Mat. nauchn. konf. porezul'tatam NIR mezhvedomstvenn. Programmy MZ i AN ArmSSRYerevan, 1985.- S. 14. 69.
- Babayan E. A. Nekotoryyemetodicheskiyevoprosygigiyenicheskogonormirovaniyakardiotoksicheskikhveshchestv v vozdukherabocheyzony / E. A. Babayan // V kn.: Probl. okhranyzdorov'yanaseleniya i zashchityokruzhayushcheysredyotkhimicheskikhvrednykhfaktorov: Tez.dokl. I Vsesoyuzn. s"yezdatoksikologov.- Rostov-na-Donu, 1986.- S. 48-49.
- Prevention of cardiac hypertrophy by angiotensin II type-2 receptor gene transfer / [Metcalfe B. L., Huentelman M. J., Parilak L. D. et al.] // Hypertension.- 2004.- V. 43.- P. 1233-1238. https://doi.org/10.1161/01.HYP.0000127563.14064.fd
- A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril- insensitive carboxypeptidase / [Tipnis S. R., Hooper N. M., Hyde R. et al.] // J Biol Chem.- 2000.- V. 275.- P. 33238-33243. https://doi.org/10.1074/jbc.M002615200
- Turner A. J. The angiotensin-converting enzyme gene family: genomics and pharmacology / A. J. Turner, N. M. Hooper // Trends Pharmacol Sci.- 2002.- V. 23.- P. 177-183. https://doi.org/10.1016/S0165-6147(00)01994-5
- Angiotensin-converting enzyme 2 is an essential regulator of heart function / [Crackower M. A., Sarao R., Oudit G. Y. et al.] // Nature.- 2002.- V. 417.- P. 822-828. https://doi.org/10.1038/nature00786
- Angiotensin-(1-7) is a modulator of the human renin-angiotensin system / [Roks A. J., van Geel P. P, Pinto Y. M. et al.] // Hypertension.- 1999.- V. 34.- P. 296-301. https://doi.org/10.1161/01.HYP.34.2.296
- Angiotensin-(1-7) attenuates vasoconstriction evoked by angiotensin II but not by noradrenaline in man / [Ueda S., Masumori-Maemoto S., Ashino K. et al.] // Hypertension.- 2000.- V. 35.- P. 998-1001. https://doi.org/10.1161/01.HYP.35.4.998
- Protection from angiotensin Il-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 / [Huentelman M. J., Grobe J. L., Vazquez J. et al.] // Exp Physiol.- 2005.- V. 90.- P. 783-790. https://doi.org/10.1113/expphysiol.2005.031096
- Cloning and characterization of a secreted form of angiotensin-converting enzyme 2 / Huentelman M. J., Zubcevic J., Katovich M. J., Raizada M. K. // RegulPept.- 2004.- V. 122.- P 61-67. https://doi.org/10.1016/j.regpep.2004.05.003
- Protection from ischemic heart injury by a vigilant heme oxygenase-1 plasmid system / [Tang Y. L., Tang Y., Zhang Y. C. et al.] // Hypertension.-2004.- V. 43.- P 746-751. https://doi.org/10.1161/01.HYP.0000120152.27263.87